Last reviewed · How we verify
SPM 907
SPM 907 is a selective antagonist of the S1P1 receptor that reduces lymphocyte egress from lymphoid tissues, thereby decreasing circulating lymphocyte counts.
SPM 907 is a selective antagonist of the S1P1 receptor that reduces lymphocyte egress from lymphoid tissues, thereby decreasing circulating lymphocyte counts. Used for Ulcerative colitis, Crohn's disease.
At a glance
| Generic name | SPM 907 |
|---|---|
| Sponsor | Pfizer |
| Drug class | S1P1 receptor antagonist |
| Target | S1P1 (Sphingosine-1-phosphate receptor 1) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By blocking sphingosine-1-phosphate receptor 1 (S1P1) on lymphocytes, SPM 907 prevents their migration from lymph nodes and spleen into peripheral blood and target tissues. This mechanism reduces pathogenic immune cell infiltration into affected organs. The drug is being developed for autoimmune and inflammatory conditions where lymphocyte-mediated tissue damage is a key pathogenic driver.
Approved indications
- Ulcerative colitis
- Crohn's disease
Common side effects
- Bradycardia
- Atrioventricular block
- Infections
- Macular edema
Key clinical trials
- Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome (PHASE3)
- Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome (PHASE3)
- Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase (PHASE2)
- A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome (PHASE3)
- Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPM 907 CI brief — competitive landscape report
- SPM 907 updates RSS · CI watch RSS
- Pfizer portfolio CI